Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase 3b Study to Evaluate Effectiveness, Safety and Pharmacokinetic Parameters of Metreleptin in Patients Under 6 Years of Age With Generalised Lipodystrophy and Associated Diabetes Mellitus and/or Hypertriglyceridaemia

NCT06502990 is registered in ClinicalTrials.gov with Amryt Pharma as lead sponsor.

NCT NCT06502990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06502990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase 3b Study to Evaluate Effectiveness, Safety and Pharmacokinetic Parameters of Metreleptin in Patients Under 6 Years of Age With Generalised Lipodystrophy and Associated Diabetes Mellitus and/or Hypertriglyceridaemia
Lead sponsor
Amryt Pharma
Phase
Phase 3
Overall status
Terminated
Start date
May 23, 2025
Completion date
February 11, 2026
Enrollment
1 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

generalized lipodystrophy